Published in Biotech Law Weekly, October 1st, 2004
Participants in the financing included Shionogi & Co., LTD., and returning investors Techno Venture Management, Oxford Bioscience Partners, BioVentures Investors, and Global Biomedical Partners. The funding will be used to advance EP-013420 in the clinic and to progress the company's discovery-stage anti-infective programs.
First in its class, EP-013420 is a bridged bicyclic ketolide that was designed by Enanta to have...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.